{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"49.31","value":"10.8"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"54.34","value":"10.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"RECIST (Response Evaluation Criteria in Solid Tumours) assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009. TTP, time in months to worsen 'progression' according to RECIST criteria. (RECIST is a set of published rules that define when cancer patients improve \"respond\", stay the same \"stable\"or worsen \"progression\" during treatments.","dispersionType":"Full Range","groups":[{"description":"Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg","id":"OG000","title":"Fulvestrant + Anastrozole"},{"description":"Anastrozole 1 mg","id":"OG001","title":"Anastrozole"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"RECIST assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009","title":"Time to Progression (TTP)","type":"PRIMARY","unitOfMeasure":"months"}